Spero Therapeutics Inc
SPRO
NASDAQ
Biotechnology
$1.23
USD
-0.01 (-0.81%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $72.09M
Volume 744.5K
Revenue
$61.19M
TTM
+37.2%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$15.23M
TTM
+121.8%
YoY
Operating Cash Flow
$7.24M
TTM
+121.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 5.9 | 14.2 | 5.4 | 41.3 | 0.3 |
YoY Growth | -36.6% | +39.1% | -59.6% | +174.5% | -95.6% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 5.9 | 14.2 | 5.4 | 41.3 | 0.3 |
Selling, General & Administrative | 6.8 | 5.9 | 4.2 | 4.3 | 4.9 |
Other Operating Expenses | 0.2 | 0.1 | 0.6 | 0.0 | 0.0 |
Total Operating Expenses | 20.6 | 16.6 | 13.4 | 9.9 | 7.8 |
Operating Income | -14.7 | -2.4 | -7.9 | 31.4 | -7.5 |
EBITDA | -14.6 | -2.4 | -7.3 | 31.4 | -7.5 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | -0.0 |
Total Other Income / Expense | 0.9 | 0.7 | 0.5 | 0.4 | 0.3 |
Income Before Income Taxes | -13.9 | -1.7 | -7.4 | 31.8 | -7.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 |
Net Income | -13.9 | -1.7 | -7.4 | 31.5 | -7.2 |
Consolidated Net Income / Loss | -13.9 | -1.7 | -7.4 | 31.5 | -7.2 |
Net Income Attributable to Common Shareholders | -13.9 | -1.7 | -7.4 | 31.5 | -7.2 |
Basic EPS | -$0.25 | -$0.03 | -$0.13 | $0.56 | -$0.13 |
Diluted EPS | -$0.25 | -$0.03 | -$0.13 | $0.46 | -$0.13 |
Basic Shares Outstanding | 55.4M | 56.0M | 56.3M | 56.4M | 57.3M |
Diluted Shares Outstanding | 55.4M | 56.0M | 56.3M | 68.5M | 57.3M |